U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06849609) titled 'A Study to Evaluate the Tolerability, Safety and Efficacy of VGN-R13 in Patients With ALS' on Feb. 23.
Brief Summary: The purpose of this trial is to evaluate safety and efficacy of intrathecal delivery of VGN-R13 as a treatment of Amyotrophic Lateral Sclerosis (ALS).
Study Start Date: Feb., 2025
Study Type: INTERVENTIONAL
Condition:
Amyotrophic Lateral Sclerosis (ALS)
Intervention:
BIOLOGICAL: VGN-R13
An adeno-associated viral vector 9 delivering human GRN and STMN2 gene.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Hong Chen
Information provided by (Responsible Party): Hong Chen, Tongji Hospital
Published by HT Digit...